Cargando…

Second-line treatment for renal cell cancer

Detalles Bibliográficos
Autores principales:	Di Lorenzo, G, De Placido, S, Buonerba, C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2012
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3322961/ https://www.ncbi.nlm.nih.gov/pubmed/22333706 http://dx.doi.org/10.1038/bjc.2011.611

Ejemplares similares

The evolving landscape in advanced penile cancer
por: Buonerba, Carlo, et al.
Publicado: (2015)

Translating new data to the daily practice in second line treatment of renal cell carcinoma: The role of tumor growth rate
por: Grande, Enrique, et al.
Publicado: (2017)

Contralateral prophylactic mastectomy in male breast cancer: where do we stand?
por: Sciarra, Antonella, et al.
Publicado: (2021)

Fisetin as an adjuvant treatment in prostate cancer patients receiving androgen-deprivation therapy
por: Lorenzo, Giuseppe Di, et al.
Publicado: (2022)

COVID-19 and prostate cancer: a complex scenario with multiple facets
por: Crocetto, Felice, et al.
Publicado: (2021)

Toll-like receptors and COVID-19: a two-faced story with an exciting ending
por: Onofrio, Livia, et al.
Publicado: (2020)

Which second line treatments after ESA failure?
por: Park, Sophie, et al.
Publicado: (2017)

Dolutegravir for second-line treatment: Programmatic implications of new evidence
por: Zhao, Ying, et al.
Publicado: (2022)

Outcomes Associated with First-Line anti-PD-1/ PD-L1 agents vs. Sunitinib in Patients with Sarcomatoid Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
por: Buonerba, Carlo, et al.
Publicado: (2020)

Third-Line Chemotherapy for Metastatic Urothelial Cancer: A Retrospective Observational Study
por: Di Lorenzo, Giuseppe, et al.
Publicado: (2015)

The Sooner, the Better: The Establishment of a Treatment Paradigm in Prostate Cancer
por: Buonerba, Carlo, et al.
Publicado: (2017)

Second line trastuzumab emtansine following horizontal dual blockade in a real-life setting
por: Prete, Salvatore Del, et al.
Publicado: (2020)

Clinical and Pathological Characteristics of Metastatic Renal Cell Carcinoma Patients Needing a Second-Line Therapy: A Systematic Review
por: Longo, Nicola, et al.
Publicado: (2020)

Second-line therapy for disseminated small-cell lung cancer: optimal management remains to be defined
por: Chouaïd, Christos, et al.
Publicado: (2020)

Efficacy of second-line chemotherapy after immunotherapy in advanced non-small cell lung cancer
por: Hirata, Tsuyoshi, et al.
Publicado: (2023)

Nature’s hidden gem: quercitrin’s promising role in preventing prostate and bladder cancer
por: Mirto, Benito Fabio, et al.
Publicado: (2023)

Optimal first-line and second-line treatments for metastatic renal cell carcinoma: current evidence
por: Sun, Maxine, et al.
Publicado: (2014)

Immune checkpoint inhibitors in penile cancer
por: Buonerba, Carlo, et al.
Publicado: (2021)

Second-line treatment in renal cell carcinoma: clinical experience and decision making
por: Guadalupi, Valentina, et al.
Publicado: (2021)

Second-Line Treatment of Metastatic Renal Cell Carcinoma in the Era of Predictive Biomarkers
por: Parosanu, Andreea Ioana, et al.
Publicado: (2023)

Docetaxel Rechallenge in a Heavily Pretreated Patient With Castration-Resistant Prostate Cancer: A Case Report and Review of Literature
por: Di Lorenzo, Giuseppe, et al.
Publicado: (2016)

Complete Response and Fatigue Improvement With the Combined Use of Cyclophosphamide and Quercetin in a Patient With Metastatic Bladder Cancer: A Case Report
por: Di Lorenzo, Giuseppe, et al.
Publicado: (2016)

Mediterranean Diet as a Supportive Intervention in Cancer Patients: Current Evidence and Future Directions
por: Rubino, Roberta, et al.
Publicado: (2022)

Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results
por: Facchini, Gaetano, et al.
Publicado: (2019)

Controversies in NSCLC: which second-line strategy after chemo-immunotherapy?
por: Moliner, L., et al.
Publicado: (2023)

Immunotherapy for penile cancer
por: Buonerba, Carlo, et al.
Publicado: (2017)

Real-world experience of everolimus as second-line treatment in metastatic renal cell cancer after failure of pazopanib
por: Koutsoukos, Konstantinos, et al.
Publicado: (2017)

Prognostic and Predictive Factors in Patients with Advanced Penile Cancer Receiving Salvage (2nd or Later Line) Systemic Treatment: A Retrospective, Multi-Center Study
por: Buonerba, Carlo, et al.
Publicado: (2016)

Second-line avelumab in platinum-treated non-small cell lung cancer patients: comment on the JAVELIN Lung 200 clinical trial
por: Rocco, Danilo, et al.
Publicado: (2019)

Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-Line Sunitinib (QUASAR): Results of a Phase I Trial
por: Buonerba, Carlo, et al.
Publicado: (2018)

Does perioperative systemic therapy represent the optimal therapeutic paradigm in organ-confined, muscle-invasive urothelial carcinoma?
por: Scafuri, Luca, et al.
Publicado: (2021)

Urologic malignancies: advances in the analysis and interpretation of clinical findings
por: Crocetto, Felice, et al.
Publicado: (2021)

Current Options for Second-Line Systemic Therapy in Metastatic Renal Cell Carcinoma
por: Mitsogiannis, Iraklis C., et al.
Publicado: (2022)

Second-line treatment options in hepatocellular carcinoma
por: Marino, Donatella, et al.
Publicado: (2019)

Survival Benefits of Second-line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma
por: Géczi, Lajos, et al.
Publicado: (2020)

Sorafenib as a second-line treatment in metastatic renal cell carcinoma in Mexico: a prospective cohort study
por: Martín-Aguilar, Ana Elena, et al.
Publicado: (2021)

Comparison of second-line treatments in metastatic renal cell carcinoma patients: A single-center experience
por: Pehlivan, Metin, et al.
Publicado: (2023)

Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)
por: De Angelis, C., et al.
Publicado: (2021)

Population-based human biomonitoring in the ‘Land of Fires’ area: innovations in study design and procedures
por: Pierri, Biancamaria, et al.
Publicado: (2020)

Pathological complete response induced by first-line chemotherapy with single agent docetaxel in a patient with advanced non small cell lung cancer
por: Riccardi, Ferdinando, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_vcmo30okescpg7hjm5sls18rp8